New Markets include Australia, New Zealand, The Netherlands, Belgium,
Luxembourg, Suriname, Italy, France, Spain, Portugal, Poland, Greece, Turkey,
and Russia
PORTOLA VALLEY, Calif., Oct. 19 /PRNewswire/ -- Spectros, developer and
manufacturer of advanced molecular sensing and imaging devices which shed
light on life-threatening diseases, announced today that it has signed
exclusive distribution deals for both its T-Stat® VLS Tissue Oximeter and
Sensors. The markets covered include Australia, New Zealand, The
Netherlands, Belgium, Luxembourg (Benelux), Suriname, Italy, France, Spain,
Portugal, Poland, Greece, Turkey, and Russia. The values of the deals were
not disclosed.
Founded in 1995, Spectros develops tissue oximeters and sensors for various
uses with applications in critical care, gastroenterology, colon-rectal
surgery, plastic surgery, and vascular surgery. T-Stat® VLS Tissue Oximeter
is an FDA-approved and CE Marking device approved for neonatal, pediatric, and
adult use.
"We are proud to be working with our new partners, Endovations in Australia,
Fysicon Medical Technology in the Netherlands, and A.M.I. Italia s.r.l. in
Italy, who are providing the T-Stat® franchise in their respective markets in
order to realize our potential," said David Benaron, CEO of Spectros.
"Support of our technology is a testament to their commitment to offering
their healthcare communities with innovative and life-saving solutions,"
commented Robert Kum, director of commercial development.
The T-Stat® franchise includes the T-Stat® VLS Tissue Oximeter, utilizing
Visible Light Spectroscopy (VLS), a multi-wavelength, noninvasive, continuous,
real-time monitor of absolute hemoglobin oxygen saturation. The T-Stat®
Sensors allow for ischemia monitoring in various applications, including
critical care (neonatal, pediatric, and adult), gastroenterology (G.I.
ischemia diagnosis), colon-rectal surgery (anastomosis), plastic surgery (free
flaps), and vascular surgery (AAA, TAAA, and EVAR).
Based in Australia, Endovations Pty. Ltd. is a leader in the field of critical
care, respiratory, anesthesia, and surgical applications. Endovations will
distributor the T-Stat® VLS Tissue Oximeter and Sensors to the Australian and
New Zealand markets.
Based in the Netherlands, Fysicon Medical Technology is a leader in the field
of cardiology. The company will distribute the T-Stat® VLS Tissue Oximeter
and Sensors to the Dutch, Belgium, and Luxembourgian (Benelux), and Suriname
markets.
Based in Italy, A.M.I. Italia s.r.l. is a leader in the patient monitoring
market. A.M.I. will distribute the T-Stat® VLS Tissue Oximeter and Sensors in
Italy, France, Spain, Portugal, Poland, Greece, Turkey, and Russia.
About Spectros
Spectros markets advanced molecular sensing and imaging devices that shed
light on ischemia and cancer. The company's lead product, the T-Stat Tissue
Oximeter, was the first medical device FDA approved as sensitive to ischemia,
an insufficient blood flow to tissue. T-Stat is the only commercially
available tissue oximeter that utilizes state-of-the-art visible light
spectroscopy (VLS) technology. In clinical use, T-Stat is a real-time,
absolute, non-invasive, and continuous tissue monitor that analyzes 260
wavelengths of light, far more than the 2-4 wavelengths used in other monitors
for superior accuracy. Spectros is also developing molecular diagnostic tools
for breast and prostate cancer currently in phase I/II clinical trials
supported by the National Cancer Institute. Spectros is a venture-supported
private concern and markets its products in the U.S. and internationally. For
further information, contact Elizabeth van Thillo, Marketing, Spectros
Corporation, at info@spectros.com or 650/529.2865
SOURCE Spectros
Elizabeth van Thillo, Marketing of Spectros Corporation, +1-650-529-2865,
info@spectros.com
